Silo Pharma, Inc.
For the period ended Aug 14, 2026. Filed Jun 30, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Aug 14, 2026 · Filed Jun 30, 2026
SILO$1.33+3.1%Stored close · as of Nov 6, 2026
Contents
Pay Versus Performance Table
| Year (1) | Summary Compensation Table Total for PEO | Compensation Actually Paid to PEO (2) | Average Summary Compensation Table Total for Non-PEO NEOs | Average Compensation Actually Paid to Non-PEO NEOs (2) | Value of Initial Fixed $100 Investment Based On Total Shareholder Return | Net Income (Loss) |
|---|---|---|---|---|---|---|
| (a) | (b) | (c) | (d) | (e) | (f) | (h) |
| 2025 | $521,750 | $498,536 | $101,494 | $95,691 | $1.60 | $(4,227,698) |
| 2024 | $630,051 | $630,051 | $88,600 | $88,600 | $6.19 | $(4,392,880) |
| 2023 | $569,009 | $569,009 | $62,692 | $62,692 | $6.79 | $(3,700,683) |
| (1) | The PEO (CEO) in the 2025, 2024 and 2023 reporting year is Eric Weisblum. The non-PEO NEOs in the 2025, 2024 and 2023 reporting year is Dan Ryweck. |
| (2) | The CAP was calculated beginning with the PEO’s SCT total. The following amounts were deducted from and added to the applicable SCT total compensation: |
| SCT Total · Stock Awards Deducted from SCT · Stock Awards Added to CAP · Stock Option Awards Deducted from SCT · Stock Option Awards Added to CAP · Total CAP A - (B + D) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (A) · (B) · (C) · (D) · (E) · + (C + E) | ||||||||||
| PEO | ||||||||||
| 2025 | $521,750 | $ | - | $ | - | $ | - | $(23,214) | $498,536 | |
| 2024 | $630,051 | $ | - | $ | - | $ | - | $ | - | $630,051 |
| 2023 | $569,009 | $ | - | $ | - | $ | - | $ | - | $569,009 |
| Average Non-PEO NEO | ||||||||||
| 2025 | $101,494 | $ | - | $ | - | $ | - | $(5,803) | $95,691 | |
| 2024 | $88,600 | $ | - | $ | - | $ | - | $ | - | $88,600 |
| 2023 | $62,692 | $ | - | $ | - | $ | - | $ | - | $62,692 |
| (3) | The fair value of stock options reported for CAP purposes in columns (C) and (E) above was estimated using a Black-Scholes option pricing model for the purposes of this PVP calculation in accordance with the SEC rules. This model uses both historical data and current market data to estimate the fair value of options and requires several assumptions. The assumptions used in estimating fair value for awards granted during 2025, 2024 and 2023 were as follows: |
| Grant Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Volatility | 206.6% – 259.3% | - | - |
| Expected life (in years) | 2.5 to 3.0 | - | - |
| Expected dividend yield | 0.0% | - | - |
| Risk-free rate | 3.73% – 3.96% | - | - |
-22-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.